950 Winter Street
About Radius HealthRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
October 3, 2003
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
Please click here for Radius Health job opportunities.
Please click here for clinical trial information.
188 articles with Radius Health
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual MeetingIncludes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between September 11-15. “We are excited that data from our histomorphometry study, showing that treatment with abaloparatide results in significant increase in bone formation in postmenopausal women with
The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel transdermal device compared with the current subcutaneous formulation, marketed as TYMLOS®.
Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference
A live webcast of the fireside presentation will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS® as well as the completion of enrollment for its Phase 3 study, which is assessing the safety and efficacy of abaloparatide-SC in men with osteoporosis.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update.
Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020
Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
Radius partner Teijin Pharma has submitted a New Drug Application for abaloparatide-SC for treatment of osteoporosis in Japan
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S. net revenue guidance mid-point reduced by 10% to between $190M and $220M. Full year cash burn is expected to be below $100M Kelly Martin appointed President and Chief Executive Officer as of Apr
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin, in connection with his appointment as Chief Executive Officer and President of the Company,
Radius Health, Inc., announced that Jesper Hoeiland will step down as President and Chief Executive Officer to return, after many years abroad, to his home country of Denmark.
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the Cowen 40th Annual Healthcare Conference in Boston at 08:40 a.m. ET on Wednesday, March 4, 2020.
TYMLOS ® U.S. net sales grew to $56 million in the fourth quarter of 2019, totaling $173M for full-year 2019, exceeding the Company’s guidance of $168 to 172M TYMLOS exited 2019 with majority share in new patients 1 , on track for market leadership in 2020 2020 TYMLOS U.S. net revenue expected to be between $220 and $235M and full-year cash burn expected to be below $80M Recruitment of three Phase 3 studies is advancing and expected to be completed in 2020, with anticipate
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the 9th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m. ET on Thursday, February 27, 2020.
Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020
Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020.
Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M.1, on track for market leadership in 2020.
Radius Health, Inc., announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:30 am PST at the Westin St. Francis Hotel in San Francisco, California.
Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)
Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio Breast Cancer Symposium, which will take place from December 10 – 14 in San Antonio, Texas.
Radius Health, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 50,000 shares of the Company’s common stock with a per share exercise price of $ 21.76, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of December 2, 2019.